|Bid||4.2500 x 900|
|Ask||4.2900 x 900|
|Day's Range||4.2200 - 4.4700|
|52 Week Range||4.2200 - 14.6200|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||4.40|
|Earnings Date||Feb 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.06|
A look at the shareholders of Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) can tell us which group is most powerful...
Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting taking place virtually on May 11-14, 2021. Oral presentations include the first reporting on the company’s novel capsid technology. The ASGCT abstracts are now available at https://www.asgct.org/, with full meeting content available for 30 days for registered attendees. Details for the oral presentations are as follows: Title: RNA-driven Evolution of AAV Capsid Libraries Identifies Variants with High Transduction Efficiency in Non-Human Primate Central Nervous SystemSession: Novel AAV Capsids for Brain, Eye and Muscle TissuesDate/time: May 11, 2021, 5:45-6:00 p.m. ETAbstract number: 51 Title: Efficacy of a Vectorized Anti-Tau Antibody Using Systemic Dosing of a Blood Brain Barrier Penetrant AAV Capsid in Mouse Models of TauopathiesSession: Preclinical Gene Therapy for Neurologic Disorders IIDate/time: May 12, 2021, 7:00-7:15 p.m. ETAbstract number: 105 Title: Separation of Empty Capsids from Full Capsids for AAV Gene Therapy Using a Flow Through and Step Elution ApproachSession: Lentivral Vector ManufacturingDate/time: May 14, 2021, 1:45-2:00 p.m. ETAbstract number: 228 Details for the poster presentations are as follows: Title: Developing an AAV Delivered Gene Therapy for Chronic Pain through Inhibition of NaV1.7 ExpressionSession: Neurologic DiseasesDate/time: May 11, 2021, 8:00-10:00 a.m. ETAbstract number: 548 Title: Ultrafiltration Behavior of Adeno-Associated Viral Vectors (AAVs) in Gene Therapy: Process Considerations for High Concentration UF/DFSession: Vector Product Engineering, Development or ManufacturingDate/time: May 11, 2021, 8:00-10:00 a.m. ETAbstract number: 835 Title: Expression of AAV Rep78 and Rep52 from Distal Baculovirus loci for Production of Gene Therapy Vectors: Proof-of-Concept and Initial OptimizationSession: Vector Product Engineering, Development or ManufacturingDate/time: May 11, 2021, 8:00-10:00 a.m. ETAbstract number: 847 Details for the digital presentations are as follows: Title: Increasing Baculovirus/Sf9 Platform Productivity by Developing a Fed-Batch Production ProcessDate: May 11-14, 2021Abstract number: 845 Title: Characterizing the Impact of Shear on SF9 Cells Used in the Baculovirus Expression System for Recombinant AAV Gene Therapy Vector ProductionDate: May 11-14, 2021 Abstract number: 856 Voyager is also presenting an Industry Sponsored Symposium titled "Advancing AAV Gene Therapy for CNS Disease," scheduled for Wednesday, May 12, 2021 at 2:00 p.m. ET. The symposium will feature the following speakers and presentations: David Schaffer, Ph.D.: “Building a Better AAV Capsid for CNS Gene Therapies” Guangping Gao, Ph.D.: “Optimizing the Transgene for AAV CNS Gene Therapies” Mark Richardson, M.D., Ph.D.: “Evolving Approaches to Direct Delivery of AAV CNS Gene Therapies” About Voyager Therapeutics Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases. For more information on Voyager Therapeutics, please visit the company’s website at www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn. Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. Investors:firstname.lastname@example.org Media:Sheryl SeapyW2Opure949email@example.com